ACIU
- AC Immune SA
()
Overview
Company Summary
AC Immune SA is a Swiss-based biotechnology company focused on developing precision medicine and innovative therapies to combat neurological diseases and neurodegenerative disorders. The company specializes in the research and development of therapeutic and diagnostic products aimed at preventing, diagnosing, and treating diseases like Alzheimer's disease (AD), Parkinson's disease (PD), and other proteinopathies.
AC Immune utilizes its proprietary technological platforms to discover and develop small molecules, antibodies, and vaccines targeting misfolded proteins associated with these neurodegenerative diseases. Their approach mainly focuses on targeting abnormal proteins, such as beta-amyloid, tau, alpha-synuclein, and TDP-43, which accumulate in the brain and contribute to the pathogenesis of neurodegeneration.
The company's pipeline includes both therapeutic candidates to treat these diseases and diagnostic agents to improve early and accurate detection. AC Immune collaborates with pharmaceutical partners and academic institutions to advance its research and development efforts while ensuring a comprehensive approach.
In addition to its research activities, AC Immune has also filed numerous patent applications and possesses an extensive intellectual property portfolio. This strengthens their position in the field, allowing them to protect and commercialize their discoveries, further enhancing their competitive advantage.
Overall, AC Immune focuses on leveraging its expertise in precision medicine and novel therapeutics to address the challenges posed by neurodegenerative diseases and improve patient outcomes through innovative treatments and diagnostics.